{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-008228","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.162549+00:00","generated_at":"2026-06-06T15:16:02.112328+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ArriVent BioPharma completes IPO of 9.7M shares at $18, raising ~$175M","bullets":["IPO of 9,722,222 shares of common stock at $18.00 per share closed January 30, 2024.","Gross proceeds to the company were approximately $175.0 million before expenses.","Amended and restated certificate of incorporation and bylaws filed and effective upon IPO closing.","Common stock trades on Nasdaq under ticker AVBP."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-008228","json":"https://secwatch.observer/filing/0001104659-24-008228.json","markdown":"https://secwatch.observer/filing/0001104659-24-008228.md","text":"https://secwatch.observer/filing/0001104659-24-008228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924008228/0001104659-24-008228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924008228/tm2321853d25_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:16:02.112328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84c4de626e560015f05fb86f9aabeca38cc6fda0","claim":"ArriVent BioPharma, Inc.: Amended and restated certificate of incorporation filed in connection with closing of IPO (effective 2024-01-30).","evidence_excerpt":"On January 30, 2024, ArriVent BioPharma, Inc. (the “Company”) filed its amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of its initial public offering (the “IPO”) of common stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924008228/0001104659-24-008228-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-01-30"}],"fact_type":"governance_change"},{"claim_id":"9dc2551b35a85f8245d5dde56eddb78fcbc28032","claim":"ArriVent BioPharma, Inc.: Adopted amended and restated bylaws in connection with closing of IPO (effective 2024-01-30).","evidence_excerpt":"The Company also adopted its amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924008228/0001104659-24-008228-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-01-30"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}